Freeline_Logo_Red_RGB.jpg
Freeline to Participate in Upcoming Investor Conferences in September 2021
September 07, 2021 07:00 ET | Freeline Therapeutics
LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline_Logo_Red_RGB.jpg
Freeline Appoints Michael J. Parini as Chief Executive Officer and Reports Second Quarter 2021 Financial Results
August 16, 2021 07:00 ET | Freeline Therapeutics
On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry...
Freeline_Logo_Red_RGB.jpg
Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Financial Results on Monday, August 16
August 13, 2021 06:30 ET | Freeline Therapeutics
LONDON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Executive Leadership Changes
June 30, 2021 16:01 ET | Freeline Therapeutics
Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief...
Freeline_Logo_Red_RGB.jpg
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
June 16, 2021 07:00 ET | Freeline Therapeutics
Lowest dose cohort complete and study positioned for dose escalation Company to present FLT190 data by year-end LONDON, June 16, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc...
Freeline_Logo_Red_RGB.jpg
Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 17, 2021 16:02 ET | Freeline Therapeutics
FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected...
Freeline_Logo_Red_RGB.jpg
Freeline Presents Data Highlighting Platform Technology at the American Society of Gene and Cell Therapy Annual Meeting 2021
May 11, 2021 07:00 ET | Freeline Therapeutics
LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline_Logo_Red_RGB.jpg
Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021
April 27, 2021 16:31 ET | Freeline Therapeutics
LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline_Logo_Red_RGB.jpg
Freeline to Participate in Upcoming Investor Conferences in April and May 2021
April 21, 2021 16:01 ET | Freeline Therapeutics
LONDON, April 21, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline_Logo_Red_RGB.jpg
Freeline Reports Full Year 2020 Financial Results and Business Highlights
March 31, 2021 16:02 ET | Freeline Therapeutics
Plans to have three AAV gene therapy programs in the clinic by year-end 2021 Data from FLT180a Phase 1/2 trial for Hemophilia B demonstrated potential for durable normalization of Factor IX...